Top

Clinical Rheumatology

Published in:

14-07-2022 | Systemic Lupus Erythematosus | Original Article

The role of MBL, PCT, CRP, neutrophil–lymphocyte ratio, and platelet lymphocyte ratio in differentiating infections from flares in lupus

Authors: Balaji Musunuri, Rina Tripathy, Sunali Padhi, Aditya K. Panda, Bidyut K. Das

Published in: Clinical Rheumatology | Issue 11/2022

Abstract

Background

The distinction between infection and flare in systemic lupus erythematosus (SLE) has always been a dilemma for clinicians as the clinical and biochemical profiles overlap. The present study evaluated affordable biomarkers to distinguish infection from flare in an SLE cohort in a tertiary care center in eastern India.

Methods

One hundred and fifty-two SLE patients were clinically evaluated and enrolled in the present study. Hematological, immunological, and biochemical profiles and various biomarkers such as C reactive protein (CRP), procalcitonin (PCT), and Mannose-binding lectin (MBL) were quantified.

Results

One hundred and fifty-two patients (152) were enrolled in the present study and all had SLEDAI scores of more than 4. From which 70 had infection, and the common infections were urinary tract infection (34.28%) followed by pneumonia (27.14%). Neutrophil–lymphocyte ratio (NLR) and C-reactive protein (CRP) were significantly elevated in SLE with infections (NLR: 5.84 ± 2.47; CRP: 30.56 ± 41.63) than those with flare (NLR: 3.87 ± 2.62; CRP: 8.73 ± 9.53). The receiver operating characteristic curve (ROC) analysis revealed CRP, PLR, and NLR as important markers for predicting infections (CRP: AUC = 0.682, p = 0.0001; PLR: AUC = 0.668, p = 0.0008; NLR: AUC = 0.742, p < 0.0001). The MBL and PCT levels were comparable among SLE flare and those with infections.

Conclusions

NLR and CRP levels are affordable biomarkers to distinguish infections from flares in SLE. MBL and PCT could not differentiate flare from an infection.

Key Points

• Biomarkers for the differentiation of infection and flare in SLE are limited.

• NLR, PLR, and CRP are promising biomarkers to enable differentiation.

• PCT and MBL are not ideal biomarkers to differentiate infection from flare.

Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15(5):308–318. https://doi.org/10.1191/0961203306lu2305xxCrossRefPubMed

Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9(5):A277-287. https://doi.org/10.1016/j.autrev.2009.12.008CrossRefPubMed

Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O (2014) Incidence of systemic lupus erythematosus in Finland, 2000–2007, a nationwide study. Clin Exp Rheumatol 32(6):953–955PubMed

Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W (2016) The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis 75(1):136–141CrossRef

Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W (2017) The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatol (Oxford) 56(11):1945–1961. https://doi.org/10.1093/rheumatology/kex260CrossRef

Siegel M, Lee SL (1973) The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 3(1):1–54. https://doi.org/10.1016/0049-0172(73)90034-6CrossRefPubMed

Gómez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcón GS, Costenbader KH (2015) Racial/ethnic variation in all-cause mortality among United States medicaid recipients with systemic lupus erythematosus: a Hispanic and Asian paradox. Arthritis Rheumatol 67(3):752–760. https://doi.org/10.1002/art.38981CrossRefPubMedPubMedCentral

González LA, Toloza SM, Alarcón GS (2014) Impact of race and ethnicity in the course and outcome of systemic lupus erythematosus. Rheum Dis Clin North Am 40(3):433–454. https://doi.org/10.1016/j.rdc.2014.04.001CrossRefPubMed

Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G (2020) Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. Rheumatol 59(11):3443–3451. https://doi.org/10.1093/rheumatology/keaa188CrossRef

10.

Duffy KN, Duffy CM, Gladman DD (1991) Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 18(8):1180–1184PubMed

11.

Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH (2003) Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus 12(9):672–676. https://doi.org/10.1191/0961203303lu452oaCrossRefPubMed

12.

Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH (2011) High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 20(6):588–597. https://doi.org/10.1177/0961203310393378CrossRefPubMed

13.

Kim HA, Jeon JY, An JM, Koh BR, Suh CH (2012) C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 39(4):728–734. https://doi.org/10.3899/jrheum.111044CrossRefPubMed

14.

Suh CH, Chun HY, Ye YM, Park HS (2006) Unresponsiveness of C-reactive protein in the non-infectious inflammation of systemic lupus erythematosus is associated with interleukin 6. Clin Immunol 119(3):291–296. https://doi.org/10.1016/j.clim.2005.11.006CrossRefPubMed

15.

Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ (2012) Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 12(2):157–163. https://doi.org/10.1016/j.autrev.2012.03.009CrossRefPubMed

16.

Luo KL, Yang YH, Lin YT, Hu YC, Yu HH, Wang LC, Chiang BL, Lee JH (2020) Differential parameters between activity flare and acute infection in pediatric patients with systemic lupus erythematosus. Sci Rep 10(1):19913. https://doi.org/10.1038/s41598-020-76789-6CrossRefPubMedPubMedCentral

17.

Wang L, Wang C, Jia X, Yang M, Yu J (2020) Relationship between neutrophil-to-lymphocyte ratio and systemic lupus erythematosus: a meta-analysis. Clinics 75:e1450. https://doi.org/10.6061/clinics/2020/e1450CrossRefPubMedPubMedCentral

18.

Panda AK, Parida JR, Tripathy R, Pattanaik SS, Ravindran B, Das BK (2013) Low producer MBL genotypes are associated with susceptibility to systemic lupus erythematosus in Odisha. India Hum Immunol 74(1):114–119. https://doi.org/10.1016/j.humimm.2012.09.003CrossRefPubMed

19.

Auriti C, Prencipe G, Moriondo M, Bersani I, Bertaina C, Mondì V, Inglese R (2017) Mannose-binding lectin: biologic characteristics and role in the susceptibility to infections and ischemia-reperfusion related injury in critically ill neonates. J Immunol Res 2017:7045630. https://doi.org/10.1155/2017/7045630CrossRefPubMedPubMedCentral

20.

Panda AK, Parida JR, Tripathy R, Pattanaik SS, Ravindran B, Das BK (2012) Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity. Arthritis Res Ther 14(5):R218. https://doi.org/10.1186/ar4057CrossRefPubMedPubMedCentral

21.

Ospina FE, Echeverri A, Zambrano D, Suso JP, Martínez-Blanco J, Cañas CA, Tobón GJ (2017) Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatol (Oxford) 56(supp1_1):46–54. https://doi.org/10.1093/rheumatology/kew340CrossRef

22.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https://doi.org/10.1002/art.1780400928CrossRefPubMed

23.

Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed

24.

Trager J, Ward MM (2001) Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 13(5):345–351. https://doi.org/10.1097/00002281-200109000-00002CrossRefPubMed

25.

Serio I, Arnaud L, Mathian A, Hausfater P, Amoura Z (2014) Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol 33(9):1209–1215. https://doi.org/10.1007/s10067-014-2738-4CrossRefPubMed

26.

Aringer M (2020) Inflammatory markers in systemic lupus erythematosus. J Autoimmun 110:102374. https://doi.org/10.1016/j.jaut.2019.102374CrossRefPubMed

27.

Panda AK, Pattanaik SS, Tripathy R, Das BK (2013) TLR-9 promoter polymorphisms (T-1237C and T-1486C) are not associated with systemic lupus erythematosus: a case control study and meta-analysis. Hum Immunol 74(12):1672–1678. https://doi.org/10.1016/j.humimm.2013.08.006CrossRefPubMed

28.

Panda AK, Tripathy R, Das BK (2021) CD14 (C-159T) polymorphism is associated with increased susceptibility to SLE, and plasma levels of soluble CD14 is a novel biomarker of disease activity: a hospital-based case-control study. Lupus 30(2):219-227. https://doi.org/10.1177/0961203320972799

29.

Stojan G, Li J, Budoff M, Arbab-Zadeh A, Petri MA (2020) High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index. Lupus Sci Med 7:1. https://doi.org/10.1136/lupus-2020-000409CrossRef

30.

Martens HA, Nolte IM, van der Steege G, Schipper M, Kallenberg CG, Te Meerman GJ, Bijl M (2009) An extensive screen of the HLA region reveals an independent association of HLA class I and class II with susceptibility for systemic lupus erythematosus. Scand J Rheumatol 38(4):256–262. https://doi.org/10.1080/03009740802552469CrossRefPubMed

31.

Mavrogeni S, Bratis K, Markussis V, Spargias C, Papadopoulou E, Papamentzelopoulos S, Constadoulakis P, Matsoukas E, Kyrou L, Kolovou G (2013) The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus Differentiation from viral myocarditis. Lupus 22(1):34–43. https://doi.org/10.1177/0961203312462265CrossRefPubMed

32.

Beca S, Rodriguez-Pinto I, Alba MA, Cervera R, Espinosa G (2015) Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. Autoimmun Rev 14(7):586–593. https://doi.org/10.1016/j.autrev.2015.02.005CrossRefPubMed

33.

Broca-Garcia BE, Saavedra MA, Martinez-Bencomo MA, Montes-Cortes DH, Jara LJ, Medina G, Vera-Lastra O, Cruz-Dominguez MP (2019) Utility of neutrophil-to-lymphocyte ratio plus C-reactive protein for infection in systemic lupus erythematosus. Lupus 28(2):217–222. https://doi.org/10.1177/0961203318821176CrossRefPubMed

34.

Maryam A Ar, Naglaa Afifi, Marwa El-Ashry (2020) Neutrophil/lymphocyte and platelet/lymphocyte ratios are useful predictors comparable to serum IL6 for disease activity and damage in naive and relapsing patients with lupus nephritis. The Egyptian Rheumatologist 42(2): 107–112. https://doi.org/10.1016/j.ejr.2019.08.002

35.

Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39(2):206–217. https://doi.org/10.1086/421997CrossRefPubMed

36.

Chirico G, Loda C (2011) Laboratory aid to the diagnosis and therapy of infection in the neonate. Pediatr Reports 3(1):1–5CrossRef

37.

Pepys MB (1981) C-reactive protein fifty years on. The Lancet 317(8221):653–657CrossRef

38.

Lanoix J, Bourgeois A, Schmidt J, Desblache J, Salle V, Smail A, Mazière J, Betsou F, Choukroun G, Duhaut P (2011) Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 20(2):125–130CrossRef

39.

Yu J, Xu B, Huang Y, Zhao J, Wang S, Wang H, Yang N (2014) Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 24(3):457–463CrossRef

40.

Ho W-L, Lan J-L, Chen D-Y, Chen Y-H, Huang W-N, Hsieh T-Y, Chen H-H, Hsieh C-W (2009) Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formos J Rheumatol 23(2):52–58

41.

Shin K, Lee Y, Kang S, Baek H, Lee E, Kim H, Song Y (2001) Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 60(10):988–989CrossRef

42.

Turner MW HR (2000) Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2(3): 305–322

43.

Garred P, Larsen F, Madsen HO, Koch C (2003) Mannose-binding lectin deficiency–revisited. Mol Immunol 40(2–4):73–84. https://doi.org/10.1016/s0161-5890(03)00104-4CrossRefPubMed

44.

Seelen MA, van der Bijl EA, Trouw LA, Zuiverloon TC, Munoz JR, Fallaux-van den Houten FC, Schlagwein N, Daha MR, Huizinga TW, Roos A (2005) A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. Rheumatol (Oxford) 44(1):111–119. https://doi.org/10.1093/rheumatology/keh417CrossRef

45.

Garred P, Madsen HO, Halberg P, Petersen J, Kronborg G, Svejgaard A, Andersen V, Jacobsen S (1999) Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 42(10):2145–2152. https://doi.org/10.1002/1529-0131(199910)42:10%3c2145::AID-ANR15%3e3.0.CO;2-#CrossRefPubMed

46.

Takahashi R, Tsutsumi A, Ohtani K, Muraki Y, Goto D, Matsumoto I, Wakamiya N, Sumida T (2005) Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus. Ann Rheum Dis 64(2):311–314. https://doi.org/10.1136/ard.2003.020172CrossRefPubMedPubMedCentral

Title: The role of MBL, PCT, CRP, neutrophil–lymphocyte ratio, and platelet lymphocyte ratio in differentiating infections from flares in lupus
Authors: Balaji Musunuri
Rina Tripathy
Sunali Padhi
Aditya K. Panda
Bidyut K. Das
Publication date: 14-07-2022
Publisher: Springer International Publishing
Keywords: Systemic Lupus Erythematosus
Biomarkers
Published in: Clinical Rheumatology / Issue 11/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-022-06285-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2022

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis

Interstitial nephritis without glomerulonephritis in ANCA-associated vasculitis: a case series and literature review

Anti-vinculin antibodies as a novel biomarker in Egyptian patients with systemic sclerosis

Correction to: Rare mutations in NLRP3 and NLRP12 associated with familial cold autoinflammatory syndrome: two Chinese pedigrees

High prevalence of necrotizing myofibers in adult dermatomyositis muscle biopsies

The skin as the first sign of a rare complication of rheumatoid arthritis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage